Galidesivir

SKU: orb1710297

Description

Galidesivir (BCX4430) is a broad-spectrum adenosine analog antiviral that functions by inhibiting viral RNA-dependent RNA polymerase. It has demonstrated in vitro activity against numerous RNA viruses and has shown efficacy in reducing lung infection in animal models, supporting its research in virology and infectious disease.

Research Area

Cell Biology, Immunology & Inflammation, Infectious Disease & Virology, Molecular Biology

Key Properties

• CAS Number: 249503-25-1
• MW: 265.27
• Purity: 96.73% (May vary between batches)
• Formula: C₁₁H₁₅N₅O₃
• SMILES: Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O
• Target: SARS-CoV,Virus Protease,Antiviral,DNA/RNA Synthesis
• Solubility: H2O:50 mg/mL (188.49 mM)

Bioactivity

• Target IC50:
  neutral red uptake assay:24.5 μM (EC50)
• In Vivo:
  Galidesivir (BCX4430) exhibits activity following intramuscular, intraperitoneal, and oral administration in various experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy.In a hamster model of Yellow Fever (YF), Galidesivir administered at 4 mg/kg via intraperitoneal injection twice daily for 7 days proves to be effective.
  Read more...
• In Vitro:
  Galidesivir (BCX4430) undergoes phosphorylation by cellular kinases to form a triphosphate that mimics ATP. The monophosphate nucleotide of the drug is then incorporated by viral RNA polymerases into the growing RNA chain, leading to premature chain termination.In inhibiting the infection of Vero cells with Yellow Fever Virus (YFV), Galidesivir demonstrates effectiveness. The EC50, as determined by the neutral red uptake assay, is 8.3 μg/ml (24.5 μM).
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BCX 4430, BCX4430, BCX-4430, Antiviral, DNASynthesis, DNA Synthesis, Immucillin-A, Galidesivir, RNA Synthesis, RNA polymerase, RNASynthesis, RdRp

Compound Identifiers

PubChem CID

10445549